Equities analysts expect that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will post earnings per share (EPS) of $0.26 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Supernus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.24 and the highest estimate coming in at $0.29. Supernus Pharmaceuticals posted earnings per share of $0.37 in the same quarter last year, which suggests a negative year over year growth rate of 29.7%. The company is scheduled to issue its next earnings results on Friday, January 19th.

On average, analysts expect that Supernus Pharmaceuticals will report full year earnings of $1.01 per share for the current year, with EPS estimates ranging from $0.89 to $1.10. For the next year, analysts expect that the firm will report earnings of $1.65 per share, with EPS estimates ranging from $1.37 to $1.99. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%.

A number of equities research analysts recently commented on the stock. Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a research report on Wednesday, July 5th. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a research report on Thursday, July 13th. Jefferies Group LLC set a $35.00 price objective on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 10th. Stifel Nicolaus reiterated a “buy” rating and set a $47.00 price target (up from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Finally, Piper Jaffray Companies downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $46.00 price target for the company. in a research report on Monday, July 17th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $48.43.

In related news, VP Padmanabh P. Bhatt sold 2,500 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $35.90, for a total transaction of $89,750.00. Following the completion of the transaction, the vice president now directly owns 37,500 shares in the company, valued at approximately $1,346,250. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 10,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $39.86, for a total value of $398,600.00. Following the transaction, the vice president now owns 27,500 shares of the company’s stock, valued at $1,096,150. The disclosure for this sale can be found here. Insiders have sold a total of 24,291 shares of company stock valued at $962,766 over the last 90 days. Insiders own 6.70% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of SUPN. BlackRock Inc. increased its position in shares of Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock valued at $209,595,000 after buying an additional 6,692,025 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock valued at $78,762,000 after buying an additional 156,094 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Supernus Pharmaceuticals by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 1,668,864 shares of the specialty pharmaceutical company’s stock valued at $52,236,000 after buying an additional 78,084 shares in the last quarter. Ranger Investment Management L.P. increased its position in shares of Supernus Pharmaceuticals by 2.8% in the first quarter. Ranger Investment Management L.P. now owns 1,482,535 shares of the specialty pharmaceutical company’s stock valued at $46,403,000 after buying an additional 40,131 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its position in shares of Supernus Pharmaceuticals by 24.5% in the second quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock valued at $58,675,000 after buying an additional 267,971 shares in the last quarter. Hedge funds and other institutional investors own 94.39% of the company’s stock.

Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 41.05 on Monday. Supernus Pharmaceuticals has a one year low of $17.25 and a one year high of $44.95. The stock has a 50 day moving average price of $42.27 and a 200 day moving average price of $33.33. The firm has a market cap of $2.07 billion, a PE ratio of 20.72 and a beta of 1.31.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to Announce $0.26 Earnings Per Share” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/07/zacks-analysts-anticipate-supernus-pharmaceuticals-inc-nasdaqsupn-to-announce-0-26-earnings-per-share.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.